Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer.

Xie M, Zheng H, Madan-Lala R, Dai W, Gimbrone NT, Chen Z, Kinose F, Blackstone SA, Smalley KSM, Cress WD, Haura EB, Rix U, Beg AA.

Cancer Res. 2019 Nov 15;79(22):5812-5825. doi: 10.1158/0008-5472.CAN-19-0698. Epub 2019 Jul 30.

PMID:
31362929
2.

Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets.

Sumi NJ, Ctortecka C, Hu Q, Bryant AT, Fang B, Remsing Rix LL, Ayaz M, Kinose F, Welsh EA, Eschrich SA, Lawrence HR, Koomen JM, Haura EB, Rix U.

Cell Chem Biol. 2019 Sep 19;26(9):1240-1252.e11. doi: 10.1016/j.chembiol.2019.06.003. Epub 2019 Jun 27.

PMID:
31257184
3.

HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma.

Faião-Flores F, Emmons MF, Durante MA, Kinose F, Saha B, Fang B, Koomen JM, Chellappan SP, Maria-Engler SS, Rix U, Licht JD, Harbour JW, Smalley KSM.

Clin Cancer Res. 2019 Sep 15;25(18):5686-5701. doi: 10.1158/1078-0432.CCR-18-3382. Epub 2019 Jun 21.

PMID:
31227503
4.

Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia.

Kuenzi BM, Remsing Rix LL, Kinose F, Kroeger JL, Lancet JE, Padron E, Rix U.

Sci Rep. 2019 Jan 24;9(1):606. doi: 10.1038/s41598-018-37174-6.

5.

Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells.

Ctortecka C, Palve V, Kuenzi BM, Fang B, Sumi NJ, Izumi V, Novakova S, Kinose F, Remsing Rix LL, Haura EB, Koomen JM, Rix U.

Mol Cell Proteomics. 2018 Dec;17(12):2434-2447. doi: 10.1074/mcp.RA118.000713. Epub 2018 Sep 14.

6.

Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines.

Verduzco D, Kuenzi BM, Kinose F, Sondak VK, Eroglu Z, Rix U, Smalley KSM.

Mol Cancer Ther. 2018 Jan;17(1):73-83. doi: 10.1158/1535-7163.MCT-17-0196. Epub 2017 Nov 13.

7.

Polypharmacology-based ceritinib repurposing using integrated functional proteomics.

Kuenzi BM, Remsing Rix LL, Stewart PA, Fang B, Kinose F, Bryant AT, Boyle TA, Koomen JM, Haura EB, Rix U.

Nat Chem Biol. 2017 Dec;13(12):1222-1231. doi: 10.1038/nchembio.2489. Epub 2017 Oct 9.

8.

Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer.

Dhawan A, Nichol D, Kinose F, Abazeed ME, Marusyk A, Haura EB, Scott JG.

Sci Rep. 2017 Apr 27;7(1):1232. doi: 10.1038/s41598-017-00791-8.

9.

Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions.

Gao B, Huang C, Kernstine K, Pelekanou V, Kluger Y, Jiang T, Peters-Hall JR, Coquelin M, Girard L, Zhang W, Huffman K, Oliver D, Kinose F, Haura E, Teer JK, Rix U, Le AT, Aisner DL, Varella-Garcia M, Doebele RC, Covington KR, Hampton OA, Doddapaneni HV, Jayaseelan JC, Hu J, Wheeler DA, Shay JW, Rimm DL, Gazdar A, Minna JD.

Oncotarget. 2017 Feb 14;8(7):11114-11126. doi: 10.18632/oncotarget.14366.

10.

Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.

Kim JY, Welsh EA, Fang B, Bai Y, Kinose F, Eschrich SA, Koomen JM, Haura EB.

Mol Cancer Res. 2016 Oct;14(10):1019-1029. Epub 2016 Jul 15.

11.

Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics.

Haake SM, Li J, Bai Y, Kinose F, Fang B, Welsh EA, Zent R, Dhillon J, Pow-Sang JM, Chen YA, Koomen JM, Rathmell WK, Fishman M, Haura EB.

Clin Cancer Res. 2016 Nov 15;22(22):5605-5616. doi: 10.1158/1078-0432.CCR-15-1673. Epub 2016 May 24.

12.

PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.

Jhuraney A, Woods NT, Wright G, Rix L, Kinose F, Kroeger JL, Remily-Wood E, Cress WD, Koomen JM, Brantley SG, Gray JE, Haura EB, Rix U, Monteiro AN.

Mol Cancer Ther. 2016 Jul;15(7):1669-81. doi: 10.1158/1535-7163.MCT-15-0182. Epub 2016 May 11.

13.

ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.

Yoshida T, Song L, Bai Y, Kinose F, Li J, Ohaegbulam KC, Muñoz-Antonia T, Qu X, Eschrich S, Uramoto H, Tanaka F, Nasarre P, Gemmill RM, Roche J, Drabkin HA, Haura EB.

PLoS One. 2016 Jan 20;11(1):e0147344. doi: 10.1371/journal.pone.0147344. eCollection 2016.

14.

Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling.

Li J, Fang B, Kinose F, Bai Y, Kim JY, Chen YA, Rix U, Koomen JM, Haura EB.

Mol Cancer Ther. 2016 Feb;15(2):334-42. doi: 10.1158/1535-7163.MCT-15-0444. Epub 2016 Jan 15.

15.

Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations.

Bai Y, Kim JY, Watters JM, Fang B, Kinose F, Song L, Koomen JM, Teer JK, Fisher K, Chen YA, Rix U, Haura EB.

Cancer Res. 2014 Dec 15;74(24):7217-7228. doi: 10.1158/0008-5472.CAN-14-0505. Epub 2014 Oct 27.

16.

GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells.

Remsing Rix LL, Kuenzi BM, Luo Y, Remily-Wood E, Kinose F, Wright G, Li J, Koomen JM, Haura EB, Lawrence HR, Rix U.

ACS Chem Biol. 2014 Feb 21;9(2):353-8. doi: 10.1021/cb400660a. Epub 2013 Nov 20.

17.

Halide ion effects on human Ether-à-go-go related gene potassium channel properties.

Zeng H, Balasubramanian B, Penniman JR, Kinose F, Salata JJ, Lagrutta A.

Assay Drug Dev Technol. 2013 Nov-Dec;11(9-10):544-50. doi: 10.1089/adt.2013.531. Epub 2013 Oct 22.

PMID:
24147984
18.

Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells.

Kim JY, Welsh EA, Oguz U, Fang B, Bai Y, Kinose F, Bronk C, Remsing Rix LL, Beg AA, Rix U, Eschrich SA, Koomen JM, Haura EB.

Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12414-9. doi: 10.1073/pnas.1220674110. Epub 2013 Jul 8.

19.

Design, synthesis, and evaluation of novel 3,6-diaryl-4-aminoalkoxyquinolines as selective agonists of somatostatin receptor subtype 2.

Wolkenberg SE, Zhao Z, Thut C, Maxwell JW, McDonald TP, Kinose F, Reilly M, Lindsley CW, Hartman GD.

J Med Chem. 2011 Apr 14;54(7):2351-8. doi: 10.1021/jm101501b. Epub 2011 Mar 11.

PMID:
21395312
20.

Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity.

Zhang G, Fang B, Liu RZ, Lin H, Kinose F, Bai Y, Oguz U, Remily-Wood ER, Li J, Altiok S, Eschrich S, Koomen J, Haura EB.

J Proteome Res. 2011 Jan 7;10(1):305-19. doi: 10.1021/pr1006203. Epub 2010 Dec 3.

21.

Improved throughput of PatchXpress hERG assay using intracellular potassium fluoride.

Zeng H, Penniman JR, Kinose F, Kim D, Trepakova ES, Malik MG, Dech SJ, Balasubramanian B, Salata JJ.

Assay Drug Dev Technol. 2008 Apr;6(2):235-41. doi: 10.1089/adt.2007.116.

PMID:
18471077
22.

Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor.

Kinose F, Roscilli G, Lamartina S, Anderson KD, Bonelli F, Spence SG, Ciliberto G, Vogt TF, Holder DJ, Toniatti C, Thut CJ.

Mol Vis. 2005 May 27;11:366-73.

23.

Tuberoinfundibular peptide of 39 residues (TIP39): molecular structure and activity for parathyroid hormone 2 receptor.

Della Penna K, Kinose F, Sun H, Koblan KS, Wang H.

Neuropharmacology. 2003 Jan;44(1):141-53.

PMID:
12559132
24.

Dorsal horn-enriched genes identified by DNA microarray, in situ hybridization and immunohistochemistry.

Sun H, Xu J, Della Penna KB, Benz RJ, Kinose F, Holder DJ, Koblan KS, Gerhold DL, Wang H.

BMC Neurosci. 2002 Aug 20;3:11.

25.

Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor.

Smith LE, Shen W, Perruzzi C, Soker S, Kinose F, Xu X, Robinson G, Driver S, Bischoff J, Zhang B, Schaeffer JM, Senger DR.

Nat Med. 1999 Dec;5(12):1390-5.

PMID:
10581081
26.

Essential role of growth hormone in ischemia-induced retinal neovascularization.

Smith LE, Kopchick JJ, Chen W, Knapp J, Kinose F, Daley D, Foley E, Smith RG, Schaeffer JM.

Science. 1997 Jun 13;276(5319):1706-9.

27.

Glycine 699 is pivotal for the motor activity of skeletal muscle myosin.

Kinose F, Wang SX, Kidambi US, Moncman CL, Winkelmann DA.

J Cell Biol. 1996 Aug;134(4):895-909.

28.

Flexibility of myosin attachment to surfaces influences F-actin motion.

Winkelmann DA, Bourdieu L, Ott A, Kinose F, Libchaber A.

Biophys J. 1995 Jun;68(6):2444-53.

29.

Motility assays using myosin attached to surfaces through specific binding to monoclonal antibodies.

Winkelmann DA, Bourdieu L, Kinose F, Libchaber A.

Biophys J. 1995 Apr;68(4 Suppl):72S.

30.

Inhibition of actin filament movement by monoclonal antibodies against the motor domain of myosin.

Winkelmann DA, Kinose F, Chung AL.

J Muscle Res Cell Motil. 1993 Aug;14(4):452-67.

PMID:
7693748

Supplemental Content

Loading ...
Support Center